- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.05. | Alto Neuroscience, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 27.05. | H.C. Wainwright reiterates Alto Neuroscience stock rating at buy | 1 | Investing.com | ||
| 22.05. | Wolfe Research startet Coverage für Alto Neuroscience mit "Outperform" | 1 | Investing.com Deutsch | ||
| 22.05. | Wolfe Research initiates Alto Neuroscience stock with outperform rating | 2 | Investing.com | ||
| 13.05. | Alto Neuroscience GAAP EPS of -$0.80 | 1 | Seeking Alpha | ||
| 13.05. | Alto Neuroscience, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 13.05. | Alto Neuroscience, Inc. - 8-K, Current Report | - | SEC Filings | ||
| ALTO NEUROSCIENCE Aktie jetzt für 0€ handeln | |||||
| 04.05. | BofA initiates Alto Neuroscience stock coverage with buy rating | 3 | Investing.com | ||
| 04.05. | Alto Neuroscience reports positive phase 2a depression trial | 1 | Investing.com | ||
| 21.04. | Alto Neuroscience launches phase 2b trial for depression drug | 3 | Investing.com | ||
| 21.04. | Alto Neuroscience, Inc.: Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression | 437 | Business Wire | - Phase 2b closely resembles PAX-D study design, which demonstrated an effect size for pramipexole more than two times larger than approved TRD therapies - - Trial design and MADRS primary endpoint... ► Artikel lesen | |
| 06.04. | H.C. Wainwright reiterates Alto Neuroscience stock rating at buy | 1 | Investing.com | ||
| 06.04. | H.C. Wainwright hält an "Buy"-Rating für Alto Neuroscience fest | 1 | Investing.com Deutsch | ||
| 01.04. | Alto Neuroscience's ALTO-101 misses primary endpoint in trial | 4 | Investing.com | ||
| 01.04. | Alto Neuroscience, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 18.03. | Stifel reiterates Buy on Alto Neuroscience stock, $33 target | 1 | Investing.com | ||
| 16.03. | Jefferies raises Alto Neuroscience stock price target on pipeline | 1 | Investing.com | ||
| 16.03. | Alto Neuroscience Shares Rise 9% After FY25 Results And $120 Mln Private Placement | - | RTTNews | ||
| 16.03. | Alto Neuroscience: $120 Million Raised To Advance Treatment-Resistant Depression Drug Candidate | 2 | pulse2.com | ||
| 16.03. | Alto Neuroscience announces $120M private placement financing | 1 | Seeking Alpha |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 77,95 | +1,43 % | Zelltherapien rücken in den Mittelpunkt: Warum Mesoblast von einem grundlegenden Wandel in der Biotechnologie profitieren könnte | ||
| EVOTEC | 4,768 | +2,41 % | Evotec nach dem Absturz: Droht noch mehr Druck auf die Aktie? | Die Aktie von Evotec bleibt nach den jüngsten Geschäftszahlen unter Druck. Zwar wächst das operative Geschäft weiter, doch sinkende Gewinne und hohe Investitionen sorgen für Verunsicherung bei Anlegern.... ► Artikel lesen | |
| MODERNA | 43,100 | -0,10 % | Fendi inszeniert Couture in der Galleria Nazionale d'Arte Moderna e Contemporanea | ||
| VALNEVA | 2,271 | -0,70 % | Was Insider bei Valneva zum Wochenstart bereits wissen: Die Entwicklung die jetzt niemand auf dem Schirm hat - Was sich am Wochenende verändert hat! | ||
| AMGEN | 305,75 | -0,39 % | Here's Why Amgen (AMGN) is Among the 7 Best Longevity Stocks to Buy Now | ||
| NOVAVAX | 7,670 | +0,13 % | Novavax (NVAX) Stock Slides as Market Rises: Facts to Know Before You Trade | ||
| BIOGEN | 173,58 | +0,43 % | Lilly, Biogen, Eisai and Genentech sponsor new 'Let's Talk Alzheimer's' podcast | ||
| PALATIN TECHNOLOGIES | 13,920 | +2,28 % | Palatin Technologies, Inc.: Palatin to Begin Trading on Nasdaq Stock Exchange | PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development... ► Artikel lesen | |
| VIVOSIM LABS | 1,140 | 0,00 % | VivoSim Labs, Inc.: VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales | SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,126 | -100,00 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Exploration of Strategic Alternatives to Maximize Value for Stakeholders | RICHMOND, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (OTCQB Venture Market: SGMO), a genomic medicine company, today announced that, after extensive consideration of the... ► Artikel lesen | |
| VIKING THERAPEUTICS | 25,150 | +1,21 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical Officer | Experienced Biotech Leader with More than Two Decades of Experience Advancing Therapies from Discovery through Regulatory Approval
SAN DIEGO, June 11, 2026 /PRNewswire/... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 10,440 | -0,19 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema | Data from HAELO Phase 3 clinical trial presented today in a late-breaking oral session at European Academy of Allergy & Clinical Immunology Annual Congress 2026HAELO manuscript simultaneously published... ► Artikel lesen | |
| TEMPUS AI | 41,375 | +0,12 % | Tempus AI study validates heart rhythm prediction software | ||
| BIOCRYST PHARMACEUTICALS | 7,142 | -5,18 % | BIOCRYST PHARMACEUTICALS INC - 8-K, Current Report | ||
| BIOMARIN PHARMACEUTICAL | 48,470 | +0,23 % | BioMarin Pharmaceutical Inc.: BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO (vosoritide) in Children with Hypochondroplasia | Study met primary endpoint, exceeding expectations with a highly statistically significant improvement in annualized growth velocity (AGV, change from baseline)... ► Artikel lesen |
Das Unternehmen ALTO NEUROSCIENCE INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 21,510 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALTO NEUROSCIENCE INC finden Sie auf Wallstreet Online.